FATE
NASDAQFate Therapeutics Inc.
News · 26 weeks63+100%
2026-04-192026-10-11
Mix1790d
- Other8(47%)
- SEC Filings4(24%)
- Leadership3(18%)
- Insider2(12%)
Latest news
25 items- PRFate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell TherapiesCommercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Jamie Harrell to its executive leadership team, effective October 12, 2026. Mr. Harrell
- PREntera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial ExpertiseTEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board. "I am delighted to welcome Laura to our Board as Entera enters an important new chapter of late-stage clinical execution, commercial preparedness for EB613 and advancement of our broader pipeline," sai
- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company’s common stock at an exercise price per share of $2.30, which was the closing price per share of the Company’s common stock as reported by NASDAQ on October 1, 2026, and (ii) restricted stock units (RSUs) represent
- PRFate Therapeutics to Participate in Upcoming Fourth Quarter 2026 ConferencesSAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026. 2026 Jefferies Global Healthcare Conference Location: London, UK Date: November 16th – 19th Piper Sandler 38th Annual Healthcare Conference Location: New York, NY Date: December 1st – 3rd The Company may participate in a presentation or a fireside chat at these conf
- SECFate Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- PRFate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the potential to provide transformative benefits to patients and the healthcare system SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that
- PRFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-11 in Orlando, Florida. Presentations span clinical, translational, and patient-centered research across the Company’s autoimmune focused, off-the-shelf, iPSC-derived CAR T-cell pipeline, including F
- PRFate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 MeetingSAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 will be featured at the Congress of Clinical Rheumatology West (CCR – West) meeting, being held in Huntington Beach, CA on September 17-20, 2026. The Company is presenting encore clinical data from the
- PRFate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare ConferenceSAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference, being held September 9–12, 2026 in New York, NY. Discussion topics will include an overview of the differentiated and favorable tolerability and meaningful clinical activity seen with FT819, the Company’s off-the-shelf CAR T-cell product candidate for the treatment of various
- PRFate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus NephritisFirst patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT designation and participation in the FDA CMC Development and Readiness Pilot program Study expected to enroll approximately 53 patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with Class III or IV lupus nephritis; study anticipated to complete enrollment in 15-18 months, by 1H2028 Patients to receive a single 900 million-cell dose of off-the-shelf FT819 following less-intensive conditioning with bendamustine; complete renal respon
- SECSEC Form S-8 filed by Fate Therapeutics Inc.S-8 - FATE THERAPEUTICS INC (0001434316) (Filer)
- SECSEC Form 10-Q filed by Fate Therapeutics Inc.10-Q - FATE THERAPEUTICS INC (0001434316) (Filer)
- SECFate Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - FATE THERAPEUTICS INC (0001434316) (Filer)
- PRFate Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesFirst lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge FDA clearance of the FT839 IND application advances the Company’s novel dual CD19/CD38 targeting off-the-shelf CAR T-cell product candidate into a Phase 1/2 basket trial in autoimmune disease Preliminary clinical data in SSc presented at the ISSCR 2026 Annual Meeting demonstrate rCRISS25 or greater responses and improvement in mRSS in all four treated patients, with no CRS, ICANS, GvHD, or hypogammaglobulinemia reported Appointment of Laura Hamill to the Board, bringi
- INSIDEROfficer Tahl Cindy sold $95,405 worth of shares (38,800 units at $2.46), decreasing direct ownership by 6% to 589,355 units (SEC Form 4) to satisfy withholding obligation4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERPresident and CEO Valamehr Bahram sold $108,101 worth of shares (43,947 units at $2.46), decreasing direct ownership by 7% to 591,815 units (SEC Form 4) (tax withholding)4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- PRFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on August 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 37,300 shares of the Company’s common stock at an exercise price per share of $2.45, which was the closing price per share of the Company’s common stock as reported by NASDAQ on July 31, 2026, and (ii) restricted stock units (RSUs) repr
- PRFate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product CandidateFirst-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited CAR T cell Built with a Suite of Genetic Edits and Manufactured as a Uniform Drug Product to Support Clinical Safety and Durable Efficacy in Autoimmune and Hematological Malignancies SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today annou
- PRFate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual MeetingSAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company’s off-the-shelf CAR T-cell product candidate, FT819, will be presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, being held at the Palais des congrès de Montréal in Montréal, Canada on July 8 - 11, 2026. The Company is participating in the Clinical Trials Update oral session and will prese
- PRFate Therapeutics to Participate in Upcoming Third Quarter 2026 ConferencesSAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the third quarter of 2026. Leerink Partners Therapeutics Forum Location: Boston, MA Date: July 14th & 15th Wells Fargo 21st Annual Healthcare Conference Location: Boston, MA Date: September 8th – 10th 12th Annual Cantor Fitzgerald Global Healthcare Conference Location: New York, NY Date: Septem
- PRA Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.USA News Group News CommentaryNEW YORK, June 30, 2026 /CNW/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company built around its proprietary natural
- INSIDERSEC Form 4 filed by Director Redmile Group, Llc4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Lee Michael Stewart4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Xu Yuan4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
- INSIDERSEC Form 4 filed by Director Jooss Karin4 - FATE THERAPEUTICS INC (0001434316) (Issuer)
FATE FAQ
7 questionsWhat does Fate Therapeutics Inc. do?
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid...Where does FATE stock trade?
Fate Therapeutics Inc. (FATE) is listed on NASDAQ.What sector and industry is FATE in?
Fate Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Fate Therapeutics Inc. go public?
Fate Therapeutics Inc. (FATE) completed its IPO in 2013.What are analysts saying about FATE?
Fate Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-05-19. Recent price targets range from $500.00 to $700.00.What companies are similar to FATE?
Notable peers in the same industry include TGTX (TG Therapeutics Inc.), TPTX (Turning Point Therapeutics Inc.), PSTX (Poseida Therapeutics Inc.), CDTX (Cidara Therapeutics Inc.). Compare FATE side-by-side with any of them on Quantisnow.How can I track FATE on Quantisnow?
Quantisnow aggregates Fate Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FATE to receive live email and push alerts on every new disclosure.